A simple and rapid LC-MS/MS method for quantitation of luseogliflozin in rat plasma and its application to a PK study.
Luseogliflozin is a novel sodium-dependent glucose cotransporter-2 inhibitor for the treatment of Type 2 diabetes mellitus. To assist pharmacokinetic and toxicodynamic studies, a rapid LC-MS/MS method were developed and validated for the quantitation of luseogliflozin in rat plasma. Sample preparation was carried out using simplified protein precipitation and liquid-liquid extraction procedures, and the run time was only 4 min. Extraction recovery was 92.9 to 95.3%, and the method was validated over the range 0.5 to 500 ng/ml for luseogliflozin with acceptable specificity, accuracy and precision. The validated method is considered suitable to quantify luseogliflozin in pharmacokinetic and pharmacodynamic/toxicodynamic studies in rats.